CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肉瘤的免疫治疗：当前数据与有前景的策略
英文原题：Immunotherapy in Sarcoma: Current Data and Promising Strategies.
查看英文原题
Immunotherapy in Sarcoma: Current Data and Promising Strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
传统上，肉瘤被认为是免疫学“冷”肿瘤，其肿瘤突变负荷（TMB）较低，肿瘤微环境（TME）具有免疫抑制性，表现为 T 细胞浸润减少以及 HIF1α、巨噬细胞和中性粒细胞水平升高。然而，研究显示，部分肉瘤属于免疫学“热”肿瘤，具有较高 TMB、PD-L1 表达、CD8+ T 细胞浸润或三级淋巴结构（TLS），因此对免疫治疗敏感。本文回顾免疫治疗用于骨肉瘤（BS）和软组织肉瘤（STS）的现有证据，包括免疫检查点抑制剂（ICI）、过继细胞疗法（如工程化 T 细胞疗法、嵌合抗原受体（CAR）T 细胞疗法、TIL（肿瘤浸润淋巴细胞）和癌症疫苗），以及疗效反应生物标志物。
展开英文摘要原文
Traditionally sarcomas have been considered immunologically quiet tumours, with low tumour mutational burden (TMB) and an immunosuppressive tumour microenvironment (TME), consisting of decreased T-cell infiltration and elevated levels of H1F1 , macrophages and neutrophils. 1,2 However, research has shown that a subset of sarcomas are immunologically 'hot' with either high TMB, PDL-1 expression, CD8+ T cells or presence of tertiary lymphoid structures (TLS) demonstrating sensitivity to immunotherapy.
3,4 Here, we review the current evidence for immunotherapy use in bone sarcomas (BS) and soft tissue sarcomas (STS), with immune checkpoint inhibitors (ICI) and adoptive cellular therapies including engineered T-cell therapies, chimeric antigen receptor (CAR) T-cell therapies, tumour infiltrating lymphocytes (TILs) and cancer vaccines and biomarkers of response.
论文信息
- 作者
- Wood GE、Meyer C、Petitprez F、D'Angelo SP
- 第一作者单位
- University College Hospital of London, London, United Kingdom.United Kingdom
- 通讯作者单位
- Memorial Sloan Kettering Cancer Center, New York, NY.United States
- 文献类型
- 综述
- 期刊
- American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2024 Jun
- 原文标识
- PubMed 38781557 · DOI 10.1200/EDBK_432234